Ozan Alkan, Ph.D. is the Head of Research for iECURE. As an accomplished scientist and pharmaceutical research and development leader, he brings more than 20 years of experience in gene therapy platform development and delivery technologies to the role. Most recently, Dr. Alkan worked at Carmine Therapeutics, where he led the support of their red blood cell extracellular vesicle gene therapy platform. Prior to that, he has held several senior leadership positions at major pharmaceutical and biotech companies, including Tidal Therapeutics, Generation Bio, and Merrimack Pharmaceuticals. Before transitioning into the industry, he worked as a research scientist and group leader at the Broad Institute of MIT and Harvard. Dr. Alkan holds a Ph.D. in cell biology from the University of Freiburg (Germany) and a M.S. in biology from the Technical University of Braunschweig (Germany). He was a visiting student in Philip Leboulch’s lab and conducted his post-doctoral research in Helen Blau’s lab at Stanford University.